Watch IMDX. Know when insiders buy.
One email the day a filing lands. Free.
IMDX
Insight Molecular Diagnostics Inc.
3.95
+0.37 +10.34%
USD · close Sep 17
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
93
PASS · shorts 93
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $129.3MP/E —DIV YIELD —FCF YIELD -23.98%REV TTM $1.7M −60.8%NET INCOME −$49.4MNET CASH $15.9M52W 2.55 – 8.48SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $239K | −53.9% | 65.7% | −$11.4M | −$11.3M | — | -0.31 | −$9.3M | $779K | −$10M | Aug 10 |
| Q1 2026 · Mar 31 | $32K | −98.5% | 46.9% | −$4.4M | −$4.3M | — | -0.12 | −$7.6M | $613K | −$8.3M | May 13 |
| Q4 2025 · Dec 31derived | $1.1M | −23.4% | 43.5% | −$23.4M | −$23M | — | -0.74 | −$5.5M | $1.5M | −$7M | Mar 26 |
| Q3 2025 · Sep 30 | $260K | +126.1% | 53.5% | −$11M | −$10.9M | — | -0.34 | −$4.6M | $1.1M | −$5.7M | Nov 10 |
| Q2 2025 · Jun 30 | $518K | +398.1% | 65.3% | −$9.8M | −$9.7M | — | -0.30 | −$6.2M | $349K | −$6.5M | Aug 10 |
| Q1 2025 · Mar 31 | $2.1M | +1114.8% | 62.0% | −$6.8M | −$6.7M | — | -0.26 | −$5.8M | $307K | −$6.1M | May 13 |
| Q4 2024 · Dec 31derived | $1.5M | +373.2% | 40.0% | −$33.6M | −$33.5M | — | -2.30 | −$5.4M | $214K | −$5.6M | Mar 26 |
| Q3 2024 · Sep 30 | $115K | −73.2% | 43.5% | −$13.5M | −$13.5M | — | -0.98 | −$5.5M | $87K | −$5.6M | Nov 10 |
| Q2 2024 · Jun 30 | $104K | — | 48.1% | −$4.6M | −$4.5M | — | -0.36 | −$6M | $191K | −$6.2M | Aug 11 |
| Q1 2024 · Mar 31 | $176K | — | 25.6% | −$9.3M | −$9.1M | — | -1.13 | −$3.8M | $24K | −$3.9M | May 12 |
| Q4 2023 · Dec 31derived | $314K | — | -37.3% | −$16.2M | −$16M | — | -2.07 | −$4.4M | $264K | −$4.7M | Mar 24 |
| Q3 2023 · Sep 30 | $429K | — | 57.8% | −$6.5M | −$6.5M | — | -0.81 | −$3.8M | — | — | Nov 12 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $4.1M | 56.7% | −$51.1M | −$50.2M | -1238.5% | -1.65 | −$22.2M | $3.2M | −$25.4M | — | — |
| FY2024 · to Dec 31 | $1.9M | 39.3% | −$61M | −$60.7M | -3225.0% | -4.66 | −$20.7M | $516K | −$21.2M | — | — |
| FY2023 · to Dec 31 | $1.5M | 27.5% | −$25.1M | −$27.8M | -1848.4% | -3.75 | −$23.3M | $281K | −$23.6M | — | — |
| FY2022 · to Dec 31 | $958K | -1.9% | −$18M | −$72.9M | -7609.8% | -13.25 | −$45.6M | $4.3M | −$49.9M | — | — |
| FY2021 · to Dec 31 | $2.2M | 64.6% | −$53.7M | −$64.1M | -2916.2% | -0.72 | −$35.9M | $2.2M | −$38.2M | — | — |
| FY2020 · to Dec 31 | $1.2M | -52.5% | −$29.7M | −$29.9M | -2461.5% | -0.46 | −$26M | $1.2M | −$27.2M | — | — |
Every number comes from Insight Molecular Diagnostics Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.